Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

The overall response rate with first-line zanubrutinib for CLL reached 97.3%, with 18.2% of patients experiencing complete response or complete response with incomplete hematologic recovery. | Image Credit: jarun011 - stock.adobe.com

Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial

By Rose McNulty

June 6th 2025

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.

People with CLL had significant mortality rates throughout the study years, which spanned the timeframe from the onset of the pandemic through February 2023. | Image credit: phonlamaiphoto - stock.adobe.com

CLL Linked With Worse COVID-19 Outcomes in Early Pandemic

By Jared Kaltwasser

May 29th 2025

Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

By AJMC Contributor

May 17th 2025

Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

By Jared Kaltwasser

May 15th 2025

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

By AJMC Contributor

May 1st 2025

More News

Gene mutation | Image Credit: © Ilya-stock.adobe.com.jpeg

March 30th 2024

Review Chronicles Advancing Insights Into Epigenetic Alterations in Chronic Lymphocytic Leukemia

Studies of DNA methylation, RNA methylation, and histone modification revealed important information about the pathology of chronic lymphocytic leukemia and treatment potential.

Lymphoma graphic| Image Credit: MP Studio - stock.adobe.com

March 27th 2024

Study Supports Use of EORTC Item Library to Assess Lymphoma Symptoms

Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.

Abstract concept of scientific research | Image Credit: kras99 - stock.adobe.com

March 23rd 2024

Review Outlines Management of Patients Receiving Venetoclax for CLL

Jared Kaltwasser

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

Chronic lymphocytic leukemia | Image Credit: momius - stock.adobe.com

March 20th 2024

Quest to Advance CLL Therapy Operating on Multiple Fronts

Jared Kaltwasser

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

Bioinformatics and Health Informatics Concept Medical and Informatics Icons on Technology Background | Image credit: ArtemisDiana - stock.adobe.com

March 16th 2024

Genomics, Transcriptomics, and Epigenomics Utilized to Better Understand Chemoimmunotherapy Resistance in CLL

Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL).

Doctor holding a test blood sample tube with leukemia test on the background of medical test tubes with analyzes | Image Credit: syhin_stas stock.adobe.com

March 13th 2024

Molecular Mapping of CLL and Richter Syndrome Offers Crucial Insights

This new analysis provides an optimistic outlook on the future of chronic lymphocytic leukemia (CLL) treatment and discoveries into the background behind CLL transformation into Richter syndrome.

Older man with cough and cold | Image Credit: © sebra - stock.adobe.com

March 8th 2024

Case Report: COVID-19 Risk in CLL Could Be Exacerbated by Hypogammaglobulinemia

Jared Kaltwasser

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery.

Man scratching a bug bite | Image credit: Oporty786 - stock.adobe.com

March 6th 2024

Case Report Shows Dupilumab Effective at Controlling Exaggerated Insect-Bite Response in Setting of CLL

Jared Kaltwasser

A patient with chronic lymphocytic leukemia (CLL) who experience persistent exaggerated responses to insect bites was successfully treated with dupilumab.

Patient and doctor | Image Credit: © DragonImages - stock.adobe.com

February 29th 2024

Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.

Cancer cell and lymphocytes | Image credit: Christoph Burgstedt-stock.adobe.com

February 28th 2024

CLL Cells Found to Secrete IL-9, Hindering Cytotoxic T-Cell Function

Jared Kaltwasser

Investigators say the findings could lead to new therapeutic targets.

Medication Management | Image Credit: © siripimon2525 - stock.adobe.com

February 24th 2024

Discontinuation of Ibrutinib Is Common in Older Patients With CLL, Study Finds

Jared Kaltwasser

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

Cancer care representation | Image credit: Nikki Zalewski - stock.adobe.com

February 19th 2024

Access to Cancer Care Alleviates Racial Disparities in CLL/SLL

No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.

Social Determinants of Health - STOATPHOTO - stock.adobe.com

February 16th 2024

Social Deprivation Independently Impacts Outcomes in Patients With Chronic Lymphocytic Leukemia

The study was the first of its kind to analyze social deprivation among CLL patients and observe the underlying reasons behind their clinical outcomes.

Lung imaging | Image credit: as-artmedia - stock.adobe.com

February 14th 2024

Mass-Like Opacities on Imaging Linked With LPI in CLL

Jared Kaltwasser

Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found.

Leukemia test against a background of medical test tubes | Image credit: syhin_stas - stock.adobe.com

February 9th 2024

Analysis: More Than Half of CLL/SLL Cases Diagnosed After 2018 Received Targeted Therapy

Jared Kaltwasser

The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing.

Questionnaire | Image credit: Richelle - stock.adobe.com

February 6th 2024

Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL

Jared Kaltwasser

Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.

leukemia disease concept - vector illustration Image credit: chrupka - stock.adobe.com

February 4th 2024

Active Hexose-Correlated Compound Shows Effectiveness in CLL

Efficacy against chronic lymphocytic leukemia (CLL) was seen when tested as both a single agent and in combination with antitumor antibody.

Ann LaCasce, MD, MMSc

February 2nd 2024

Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.

Chronic lymphocytic leukemia cells in blood flow-isometric view | Image credit: LASZLO - stock.adobe.com

January 26th 2024

In CLL, BTK-Inhibitor Resistance Remains a Confounding Problem

Jared Kaltwasser

Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).

Chronic lymphocytic leukemia | Image credit: momius - stock.adobe.com

January 23rd 2024

Study: CLL Therapies Cannot Overcome Increased Infection, Malignancy Risk

Jared Kaltwasser

A new report compared the blood immune repertoires of patients with chronic lymphocytic leukemia (CLL) who received chemoimmunotherapy and those who received ibrutinib.

January 20th 2024

ASH Abstracts Showcase Effective Treatments for MM, CLL, FL

Skylar Jeremias

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Cancer treatment, doctor supporting patient | Image credit: catalin - stock.adobe.com

January 19th 2024

Real-World Study Confirms Efficacy of Venetoclax Alone, After BTKi Therapy in CLL

Skylar Jeremias

Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).

January 17th 2024

Data Reveal Racial, SDOH Factors Linked to OS Differences in CLL

Interview by Mary Caffrey

Chronic lymphocytic leukemia - LASZLO - stock.adobe.com

January 12th 2024

Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL

A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.

Chronic lymphocytic leukemia in blood | Image credit: LASZLO - stock.adobe.com

January 10th 2024

Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups

Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.

Image credit: jarun011 - stock.adobe.com

January 5th 2024

Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era

An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.

CLL Society’s Koffman Says ASH 2023 Offered “Evolutionary” Changes

January 2nd 2024

CLL Society’s Koffman Says ASH 2023 Offered “Evolutionary” Changes

Interview by Mary Caffrey

Jaypirca | Image credit: Eli Lilly

December 2nd 2023

FDA Grants Accelerated Approval to Pirtobrutinib for Patients With CLL/SLL After Use of BTK, BCL-2 Inhibitors

The therapy is already approved for certain patients with relapsed/refractory mantle cell lymphoma.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute

August 23rd 2023

Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL

Skylar Jeremias Rose McNulty

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy

August 3rd 2023

Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy

Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions